Current consensus on the management of primary sclerosing cholangitis

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue 12, 2011, Pages 786-791

  Wiencke, K ^a   Boberg, K M ^b  

^a VESTRE VIKEN HOSPITAL TRUST   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCIUM; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PENTOXIFYLLINE; PIRFENIDONE; TACROLIMUS; URSODEOXYCHOLIC ACID; VITAMIN D;

BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; CANCER RISK; CHEMOPROPHYLAXIS; CHOLESTASIS; CLINICAL TRIAL (TOPIC); COLON CANCER; COLONOSCOPY; COLORECTAL CANCER; CONSENSUS DEVELOPMENT; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG MEGADOSE; ENDOSCOPIC THERAPY; ENTERITIS; GALLBLADDER CANCER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; METABOLIC BONE DISEASE; OSTEOPOROSIS; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PRIMARY SCLEROSING CHOLANGITIS; PRURITUS; SHORT SURVEY; STENT; ULTRASOUND; CONSENSUS; REVIEW; SCLEROSING CHOLANGITIS;

CHOLANGITIS, SCLEROSING; CONSENSUS; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84857190289     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.04.007     Document Type: Short Survey

References (43)

1. Lee Y.M., Kaplan M.M. Primary sclerosing cholangitis. N Engl J Med 1995, 332:924-933.
2. Tischendorf J.J., Hecker H., Kruger M., et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007, 102:107-114.
3. Broome U., Olsson R., Loof L., et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996, 38:610-615.
4. Bambha K., Kim W.R., Talwalkar J., et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003, 125:1364-1369.
5. Saarinen S., Olerup O., Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 2000, 95:3195-3199.
6. Hov J.R., Boberg K.M., Karlsen T.H. Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol 2008, 14:3781-3791.
7. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51:237-267. EASL Clinical Practice Guidelines.
8. Chapman R., Fevery J., Kalloo A., et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010, 51:660-678.
9. Bjornsson E., Boberg K.M., Cullen S., et al. Patients with small duct primary sclerosing cholangitis have a favourable long-term prognosis. Gut 2002, 51:731-735.
10. Boberg K.M., Chapman R.W., Hirschfield G.M., et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011, 54:374-385.
11. Loftus E.V., Harewood G.C., Loftus C.G., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005, 54:91-96.
12. Jorgensen K.K., Grzyb K., Lundin K.E., et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis 2011, Mar 31 (Epub ahead of print). 10.1002/ibd.21699.
13. Bergquist A., Ekbom A., Olsson R., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002, 36:321-327.
14. Levy C., Lymp J., Angulo P., et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005, 50:1734-1740.
15. Boberg K.M., Jebsen P., Clausen O.P., et al. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2006, 45:568-574.
16. Moreno L.L.E., Kipp B., Halling K.C., et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006, 131:1064-1072.
17. Karlsen T.H., Schrumpf E., Boberg K.M. Gallbladder polyps in primary sclerosing cholangitis: not so benign. Curr Opin Gastroenterol 2008, 24:395-399.
18. Broome U., Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006, 26:31-41.
19. Soetikno R.M., Lin O.S., Heidenreich P.A., et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002, 56:48-54.
20. Cullen S.N., Chapman R.W. Review article: current management of primary sclerosing cholangitis. Aliment Pharmacol Ther 2005, 21:933-948.
21. Sinakos E., Lindor K. Treatment options for primary sclerosing cholangitis. Expert Rev Gastroenterol Hepatol 2010, 4:473-488.
22. Gregorio G.V., Portmann B., Karani J., et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001, 33:544-553.
23. Bjornsson E. Immunoglobulin G4-associated cholangitis. Curr Opin Gastroenterol 2008, 24:389-394.
24. Beuers U., Spengler U., Kruis W., et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992, 16:707-714.
25. Lindor K.D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997, 336:691-695.
26. Mitchell S.A., Bansi D.S., Hunt N., et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001, 121:900-907.
27. Olsson R., Boberg K.M., de M O.S., et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005, 129:1464-1472.
28. Lindor K.D., Kowdley K.V., Luketic V.A., et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009, 50:808-814.
29. Tung B.Y., Emond M.J., Haggitt R.C., et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001, 134:89-95.
30. Pardi D.S., Loftus E.V.J., Kremers W.K., et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889-893.
31. Wolf J.M., Rybicki L.A., Lashner B.A. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005, 22:783-788.
32. Brandsaeter B., Isoniemi H., Broome U., et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. Journal of Hepatology J Hepatol 2004, 40:815-822.
33. Paumgartner G. Biliary physiology and disease: reflections of a physician-scientist. Hepatology 2010, 51:1095-1106.
34. Rudolph G., Gotthardt D., Kloters-Plachky P., et al. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol 2009, 51:149-155.
35. Baluyut A.R., Sherman S., Lehman G.A., et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001, 53:308-312.
36. Bjornsson E., Lindqvist-Ottosson J., Asztely M., et al. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 2004, 99:502-508.
37. Kaya M., Petersen B.T., Angulo P., et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 2001, 96:1059-1066.
38. Ponsioen C.Y., Lam K., van Milligen de Wit A.W., et al. Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol 1999, 94:2403-2407.
39. Brandsaeter B., Broome U., Isoniemi H., et al. Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list. Liver Transpl 2003, 9:961-969.
40. Alabraba E., Nightingale P., Gunson B., et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009, 15:330-340.
41. Gores G.J., Nagorney D.M., Rosen C.B. Cholangiocarcinoma: is transplantation an option? For whom?. J Hepatol 2007, 47:455-459.
42. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
43. Garcia-Tsao G., Sanyal A.J., Grace N.D., et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007, 46:922-938.